These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23230323)

  • 1. Predicting the cost and pace of pharmacogenomic advances: an evidence-based study.
    Arnaout R; Buck TP; Roulette P; Sukhatme VP
    Clin Chem; 2013 Apr; 59(4):649-57. PubMed ID: 23230323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics and therapeutic strategies for dementia.
    Cacabelos R
    Expert Rev Mol Diagn; 2009 Sep; 9(6):567-611. PubMed ID: 19732004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cost-effectiveness analysis in the era of pharmacogenomics.
    Flowers CR; Veenstra D
    Pharmacoeconomics; 2004; 22(8):481-93. PubMed ID: 15217305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic potential of psychiatric medications and CYP2D6.
    Foley KF; Quigley DI
    MLO Med Lab Obs; 2010 Jan; 42(1):32-4. PubMed ID: 20180465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
    Becquemont L
    Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.
    Lauschke VM; Milani L; Ingelman-Sundberg M
    AAPS J; 2017 Nov; 20(1):4. PubMed ID: 29181807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric perspective on pharmacogenomics.
    Stevens A; De Leonibus C; Hanson D; Whatmore A; Murray P; Donn R; Meyer S; Chatelain P; Clayton P
    Pharmacogenomics; 2013 Nov; 14(15):1889-905. PubMed ID: 24236488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies.
    Samwald M; Miñarro Giménez JA; Boyce RD; Freimuth RR; Adlassnig KP; Dumontier M
    BMC Med Inform Decis Mak; 2015 Feb; 15():12. PubMed ID: 25880555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy.
    Mitropoulos K; Cooper DN; Mitropoulou C; Agathos S; Reichardt JKV; Al-Maskari F; Chantratita W; Wonkam A; Dandara C; Katsila T; Lopez-Correa C; Ali BR; Patrinos GP
    OMICS; 2017 Nov; 21(11):647-657. PubMed ID: 29140767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics at 50: genomic personalization comes of age.
    Urban TJ; Goldstein DB
    Sci Transl Med; 2014 Jan; 6(220):220ps1. PubMed ID: 24452261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.
    Bottorff MB; Bright DR; Kisor DF
    Pharmacotherapy; 2017 Sep; 37(9):1005-1013. PubMed ID: 28654154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based pharmacogenetics: Is it possible?
    Sychev DA; Malova EU
    Int J Risk Saf Med; 2015; 27 Suppl 1():S97-8. PubMed ID: 26639733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disclosure of individual pharmacogenomic results in research projects: when and what kind of information to return to research participants.
    Korol S; Hurlimann T; Godard B; de Denus S
    Pharmacogenomics; 2013 Apr; 14(6):675-88. PubMed ID: 23570470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics: Principles and Relevance to Oncology Nursing
.
    Dodson CH
    Clin J Oncol Nurs; 2017 Dec; 21(6):739-745. PubMed ID: 29149126
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.